Autoimmune thyroid diseases;Autoimmune schilddrüsenerkrankungen

Deutsches Arzteblatt

Volumn 103, Issue 45, 2006, Pages

  Schott, Matthias ^a   Scherbaum, Werner A ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Autoimmune disease; Graves' disease; Hyperthyroidism; Hypothyroidism; Thyroid disease

Indexed keywords

AUTOANTIGEN; PEROXIDASE; THYREOPEROXIDASE; THYROTROPIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

BLOOD FLOW; GRAVES DISEASE; HASHIMOTO DISEASE; HEREDITY; HUMAN; HYPOTHYROIDISM; IMMUNOASSAY; MEDICAL LITERATURE; PATHOGENESIS; REVIEW;

EID: 33751522300     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR: Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 1998; 83: 765-9.
2. Quaratino S, Badami E, Pang YY, Bartok I, Dyson J, Kioussis D et al.: Degenerate self-reactive human T-cell receptor causes spontaneous autoimmune disease in mice. Nat Med 2004; 10: 920-6.
3. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA: Different cytokine mRNA profiles in Graves' disease, Hashimoto's thyroiditis, and nonautoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 1996; 6: 97-106.
4. Imaizumi M, Pritsker A, Linger P, Davies TF: intrathyroidal fetal microchimerism in pregnancy and postpartum. Endocrinology 2002; 143: 247-53.
5. Mariotti S, Sansoni P, Barbesino G et al.: Thyroid and other organ-specific autoantibodies in healthy centenarians. Lancet 1992; 339: 1506-8.
6. Vanderpump MP, Tunbridge WM, French JM et al.: The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68.
7. Hollowell JG, Staehling NW, Flanders WD et al.: Serum TSH, J(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-99.
8. Surks MI, Ortiz E, Daniels GH et al.: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.
9. Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86: 930-4.
10. Holm IA, Manson JE, Michels KB, Alexander EK, Willett WC, Utiger RD: Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med 2005; 165: 1606-11.
11. Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies T: A monoclonal thyroid-stimulating antibody. J Clin Invest 2002; 110: 1667-74.
12. Costagliola S, Franssen JD, Bonomi M et al.: Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem Biophys Res Commun 2002; 299: 891-6.
13. Sanders J, Evans M, Premawardhana LD et al.: Human monoclonal thyroid stimulating autoantibody. Lancet 2003; 362: 126-8.
14. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE: Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83: 998-1002.
15. Costagliola S, Morgenthaler NG, Hoermann R et al.: Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab 1999; 84: 90-7.
16. Morgenthaler NG: New assay systems for thyrotropin receptor antibodies. Curr Opin Endocrinol Diabetes 1999; 6: 251-60.
17. Maugendre D, Massart C: Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001; 54: 89-96.
18. Massart C, Orgiazzi J, Maugendre D: Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Clin Chim Acta 2001; 304: 39-47.
19. Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA, Seissler J: Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000; 32: 429-35.
20. Schott M, Morgenthaler NG, Fritzen R et al.: Levels of autoantibodies against human TSH receptor predict relapse of hyper-thyroidism in Graves' disease. Horm Metab Res 2004; 36: 92-6.
21. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE: Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease. Thyroid 2005; 15: 1047-54.
22. Eckstein AK, Plicht M, Lax H et al.: Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612-8.
23. Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA: Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res 1998; 30: 162-8.
24. Schott M, Minich WB, Willenberg HS et al.: Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res 2005; 37: 741-4.
25. Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE: Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment. Horm Metab Res 2005; 37: 745-50.